Pluto Bio Raises $3.6M to Expand AI-Powered Multi-Omics Analysis Platform for Pharma
Funding led by new investor Kickstart, with continued support from Silverton Partners and other investors
DENVER–(BUSINESS WIRE)–Pluto Bio, the leading, AI-powered platform for computational biology, today announced it has raised $3.6 million in new funding to accelerate growth and scale adoption of its enterprise-grade platform among global pharma companies. The round includes participation from new investor Kickstart, alongside existing investor Silverton Partners and existing angel investors.
Pluto’s platform serves as the industry’s most powerful “canvas for computational biology” – a secure, collaborative environment where scientists at therapeutics companies explore large, high-dimensional datasets, run auto-scaling bioinformatics pipelines, and generate publication-ready visualizations tailored to their specific scientific questions without writing code. As large language models (LLMs) reshape drug discovery and development, Pluto is at the forefront of empowering biology and translational medicine teams to harness AI in a manner that complements the vital insights from human scientists.
